Pre-Operative Intravitreal Injection of Bevacizumab In Patients With Diabetic Macular Edema Undergoig Phacoemulsification

Authors

  • Imran Ahmad
  • Muhammad Tariq Khan
  • Muhammad Zeeshan Tahir
  • Mubashir Rehman
  • Jehanzeb Khan
  • Javid Rasool
  • Akbar Khan

DOI:

https://doi.org/10.52206/jsmc.2019.9.2.%25p

Keywords:

Intravitreal, Bevacizumab, Diabetic macular edema, Phacoemulsification

Abstract

Background: Diabetes is a common disease worldwide. The most common cause of decrease vision in diabetics is diabetic
macular edema. Cataract develops early in diabetics in comparison to normal population. Phacoemulsification is associated with
aggravating macular edema in diabetes. Bevacizumab is anti-VEGF used for the treatment of diabetic macular edema.
Objective: To determine that pre-operative intravitreal injection of bevacizumab prevents increase in diabetic macula edema and
help in improvement of macular edema on optical coherence tomography (OCT).
Material and Methods: The study was conducted in Bacha Khan Medical Complex swabi from March 2017 to February 2019.
Results: A total of 120 patients were included in the study with 68 male and 52 female patients with mean age of 58.74 + 4.82. In all patients there was no futher increase in diabetic macular edema documented on OCT post-operatively after pre-operative intravitreal injection of bevacizumab.

Conclusion: Pre-operative intravitreal anti-VEGF prevents the aggravation of diabetic macular edema and results an
improvement in macular thickness on optical coherence tomography.

Downloads

Published

21-01-2020

How to Cite

1.
Ahmad I, Khan MT, Tahir MZ, Rehman M, Khan J, Rasool J, Khan A. Pre-Operative Intravitreal Injection of Bevacizumab In Patients With Diabetic Macular Edema Undergoig Phacoemulsification. J Saidu Med Coll [Internet]. 2020 Jan. 21 [cited 2025 Jun. 12];9(2). Available from: http://jsmc.pk/index.php/jsmc/article/view/221

Issue

Vol. 9 No. 2 (2019): Journal of Saidu Medical College

Section

Original Article

License

Copyright (c) 2020 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.